Rifampicin-Theophylline-DDI

Modeling of published clinical Rifampicin-Theophylline-DDI studies for model evaluation

Repository files

Within this repository, we distribute a PK-Sim project file containing simulations of all published clinical studies used to evaluate the predictive performance of our models regarding the Rifampicin-Theophylline-DDI, including the respective observed data digitized from literature reports. The applied rifampicin model is an extended version of the rifampicin model published previously. For further details and documentation please refer to [1].

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model code is distributed under the GPLv2 License.

Reference

[1] Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T. PBPK models for CYP1A2 DDI prediction: a modelling network of fluvoxamine, theophylline, caffeine, rifampicin and midazolam. CPT Pharmacometrics Syst Pharmacol 2019, https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/psp4.12397.